All In Biotech

Drug Trial Radar · NCT06596772

A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis

A Prospective, Randomized, Double-blind, Parallel-group Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of MB04 and EU-sourced Enbrel® in Patients With Moderate to Severe Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 501 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

501

Actual

Start

Oct 3, 2024

Primary completion

Feb 20, 2026

Study completion Feb 20, 2026

Sponsor

Lead sponsor
mAbxience Research S.L.Industry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 \[proposed etanercept biosimilar\] to Enbrel® \[EU-sourced\] in rheumatoid arthritis

Conditions

  • Rheumatoid Arthritis (RA)

Interventions

  • MB04 (proposed biosimilar to etanercept)Drug

    MB04 50 mg/week via subcutaneous injection

  • Enbrel (etanercept)Drug

    Enbrel 50 mg/week via subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. American College of Rheumatology 20% Response Criteria (ACR20)Time frame: Week 24

Locations

60 sites in 6 countries. Site status is shown where the registry gives one.

  • Research site 2007

    Haskovo, Bulgaria

  • Research site 2005

    Plovdiv, Bulgaria

  • Research Site 2002

    Rousse, Bulgaria

  • Research site 2001

    Sofia, Bulgaria

  • Research Site 2003

    Sofia, Bulgaria

  • Research Site 2008

    Sofia, Bulgaria

  • Research site 2004

    Vidin, Bulgaria

  • Research site 2006

    Vratsa, Bulgaria

  • Research site 7004

    Batumi, Georgia

  • Research site 7010

    Batumi, Georgia

  • Research site 7001

    Tbilisi, Georgia

  • Research site 7002

    Tbilisi, Georgia

  • Research site 7003

    Tbilisi, Georgia

  • Research site 7005

    Tbilisi, Georgia

  • Research site 7006

    Tbilisi, Georgia

  • Research site 7007

    Tbilisi, Georgia

  • Research site 7009

    Tbilisi, Georgia

  • Research Site 1301

    Chisinau, Moldova

  • Research site 1302

    Chisinau, Moldova

  • Research site 1303

    Chisinau, Moldova

  • Research Site 1603

    Bialystok, Poland

  • Research Site 1614

    Bialystok, Poland

  • Research site 1616

    Bialystok, Poland

  • Research site 1613

    Bydgoszcz, Poland

  • Research site 1623

    Bytom, Poland

  • Research Site 1615

    Elblag, Poland

  • Research Site 1627

    Elblag, Poland

  • Research Site 1606

    Gdynia, Poland

  • Research Site 1611

    Katowice, Poland

  • Research Site 1617

    Krakow, Poland

  • Research Site 1622

    Lublin, Poland

  • Research site 1605

    Nowa Sól, Poland

  • Research Site 1618

    Opole, Poland

  • Research site 1628

    Piotrkow Trybunalski, Poland

  • Research Site 1624

    Poniatowa, Poland

  • Research Site 1601

    Poznan, Poland

  • Research Site 1602

    Poznan, Poland

  • Research Site 1608

    Poznan, Poland

  • Research Site 1619

    Poznan, Poland

  • Research Site 1621

    Poznan, Poland

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.